Romania has once again proved fertile ground for Swissray, which is selling the Romanian government 30 ddRChest-Systems for more than $7 million, in addition to the 32 ddRMulti-Systems delivered earlier this year for $13.8 million.Swissray reported its
Romania has once again proved fertile ground for Swissray, which is selling the Romanian government 30 ddRChest-Systems for more than $7 million, in addition to the 32 ddRMulti-Systems delivered earlier this year for $13.8 million.
Swissray reported its first-ever positive cash flow from operating activities (SCAN, 10/11/00). The Switzerland-based company said it has sold or contracted for more than 100 ddR systems worldwide. The company hopes to surpass this figure in 2001.
Swissray was delisted from the NASDAQ stock exchange in 1998 after its stock steadily declined to a per-share price below $1. With sales now climbing, the company hopes to be relisted soon.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.